HeartBeam gets European patent for signal transformation

HeartBeam announced that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo credit card-sized device was issued by the European Patent Office. This patent offers protection for HeartBeam’s flagship technology in multiple countries in Europe and has been validated in France, Germany, Netherlands and the United Kingdom. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis. According to data from the European Society of Cardiology ESC , more than 11M new cases of cardiovascular disease CVD occur in Europe as a whole, every year, with almost 49M people living with the disease in the EU alone at a cost as of EUR 210B a year. CVD remains the leading cause of mortality and a major cause of morbidity in Europe. A 12-lead ECG is the standard of care for detecting any cardiac condition and is considered one of the essential tools for heart attack detection. No single lead ECG product currently in the marketplace is able to help diagnose a heart attack. HeartBeam’s technology will be the first and only 12-lead ECG solution that fits in a consumer’s wallet for use anytime, anywhere. "This initial European patent strengthens our intellectual property protection for our HeartBeam AIMIGo technology offering 12-lead ECG capability as we expand our product applications to reach a variety of regions in the global marketplace," said HeartBeam CEO and Founder Branislav Vajdic, Ph.D. "We continue to enhance our intellectual property to provide protection of our technology in priority global markets."